Poster SESSIONS
74
Poster, 25 June 2014
P-43
POSTER SESSION
17:15–18:45
Hall B
Schizophrenia C
P-43-001
White matter alterations in first-episode defi-
cit and non-deficit schizophrenia patients
and their first-degree relatives – a combin-
ing TBSS and VBM study
Wei Lei, Chengdu, China
W. Deng, T. Li
P-43-002
Gray matter alterations in first-episode pa-
tients with deficit or non-deficit schizophre-
nia and their first-degree relatives
Wei Lei, Chengdu, China
W. Deng, M. Li, N. Zhang, T. Li
P-43-003
The contingent negative variation in patients
with deficit schizophrenia and or bipolar I
disorder patients with psychotic features
measurement and correlation with clinical
characteristics
Zhe Li, Chengdu, China
W. Deng, X. Liu, Z. Zheng, M. Li, X. Ma, Q.
Wang, T. Li
P-43-004
Effects of the putative antipsychotics D- and
L-govadine on disrupted performance of the
touchscreen-based paired associates task
following acute MK-801 in rats
Brittney Lins, Saskatoon, Canada
A. Phillips, J. Howland
P-43-005
Neuroimmunoendocrine interrelationships
in long-term treatment of schizophrenic pa-
tients with quetiapine
Olga Lobacheva, Tomsk, Russia
T. Vetlugina, A. Semke, Y. Maltseva
P-43-006
Evaluation of daytime sleepiness in patients
with schizophrenia treated with atypical
antipsychotics: Results from a randomized,
double-blind, placebo-controlled trial
Antony Loebel, Fort Lee, USA
C. Siu, J. Cucchiaro, A. Pikalov, P. Harvey
P-43-007
BDNF polymorphisms are associated with
schizophrenia onset and cognitive perfor-
mance
Menghan Lv, Beijing, China
X. Zhang
P-43-008
Divergent quantitative and qualitative
changes in amphetamine-induced hyperlo-
comotion in BDNF heterozygous mice fol-
lowing chronic methamphetamine exposure
Elizabeth Manning, Parkville, Australia
A. Halberstadt, M. van den Buuse
P-43-009
An open-label extension study of lurasidone
safety and efficacy in patients with schizo-
phrenia previously randomized to lurasidone
or risperidone
Gregory Mattingly, St. Charles, USA
M. Tocco, J. Cucchiaro, J. Xu, A. Loebel
P-43-010
Early response to risperidone treatment in
the first episode of schizophrenia (FES) pa-
tients and its predictive value to subsequent
response
Michaela Mayerova, Brno, Czech Republic
L. Ustohal, I. Stehnova, R. Prikryl, E. Ceskova,
T. Kasparek
P-43-011
The electronic schizophrenia treatment adher-
ence registry-e-STAR. Results from Romania
Ioana Valentina Miclutia, Clujnapoca, Romania
D. M. Podea, L. Damian, I. D. Craciun, R. Ciungu
P-43-012
Prospective naturalistic survey of safety of
risperidone long acting injectable (RLAI) in
Romanian schizophrenia patients
Ioana Valentina Miclutia, Clujnapoca, Romania
D. M. Podea, M. Vrabie, R. Ciungu
P-43-013
Lurasidone in contrast to other antipsychot-
ics does not produce deficits in social ex-
ploration and social recognition in the rat
Pawel Mierzejewski, Warsaw, Poland
N. Nowak, A. Glebicka, K. Karas, M. Kolacz-
kowski, P. Bienkowski
P-43-014
Effect of long-term treatment with lurasi-
done or risperidone on metabolic syndrome
status in patients with schizophrenia
John Newcomer, Boca Raton, USA
A. Pikalov, K. Watabe, J. Cucchiaro, K. Rajago-
palan, A. Loebel
